Compare CVS Health Corp (CVS) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs NEOS S&P 500 High Income ETF — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: CVS Health Corp is far larger — about 9× NEOS S&P 500 High Income ETF's market cap, and CVS Health Corp pays a 3.03% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| CVS | SPYI | |
|---|---|---|
Market Cap | $112.29B | $12.50B |
Volume | 7,763,676 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $110.60 | $54.42 |
52-Week Low | $70.08 | $47.98 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
